Weiyu Zhang, Huixin Liu, Ming Liu, Shi Ying, Renbin Yuan, Hao Zeng, Zhenting Zhang, Sujun Han, Zhannan Si, Bin Hu, Simeng Wen, Pengcheng Xu, Weimin Yu, Hui Chen, Liang Wang, Zhitao Lin, Tao Dai, Yunzhi Lin, Tao Xu
BACKGROUND: Cardiovascular disease (CVD) has emerged as the leading cause of death from prostate cancer (PCa) in recent decades, bringing a great disease burden worldwide. Men with preexisting CVD have an increased risk for major adverse cardiovascular events when treated with androgen deprivation therapy (ADT). The present study was aimed to explore the prevalence and risk evaluation of CVD among people with newly diagnosed PCa in China. METHODS: Clinical data of newly diagnosed PCa patients were retrospectively collected from 34 centers in China from 2010 to 2022 through convenience sampling...
April 12, 2024: Chinese Medical Journal